Department of Pharmacy, 920th Hospital of Joint Logistics Support Force, Kunming, China.
Department of Orthopaedics, General Hospital of South Theatre, Guangzhou, China.
Gynecol Endocrinol. 2020 Jul;36(7):626-631. doi: 10.1080/09513590.2020.1727431. Epub 2020 Feb 18.
Osteoporosis is now a worldwide public health problem that seriously endangers human health, but its causes have not yet been fully clarified. Recently, increasing evidence suggested that polymorphisms in gene were associated with osteoporosis risk and bone mineral density (BMD), but results remained conflicting. We herein performed a meta-analysis based on evidence currently available from the literature to make a more precise estimation of these relationships. The PubMed, Embase, Cochrane library, CNKI (China National Knowledge Infrastructure), and Wan Fang databases were searched for eligible studies. Odds ratio (OR), mean difference (MD), and 95% confidence interval (CI) were applied to assess the strength of these relationships. A total of 8 studies involving 2632 subjects were included in our meta-analysis. We observed that the AG genotype of rs700518 was significantly associated with lower BMD values of lumbar spine and femoral neck (AG vs. GG: = .001 and.01, respectively). However, this polymorphism had no obvious impacts on osteoporosis risk according to current available data. In conclusion, the present meta-analysis showed that rs700518 polymorphism may be a potential candidate biomarker for osteoporosis screening, early diagnosis, and treatment, which will help improve individualized therapy of osteoporosis patients in clinics.
骨质疏松症是一种全球性的公共卫生问题,严重威胁着人类健康,但病因尚未完全阐明。最近,越来越多的证据表明基因中的多态性与骨质疏松症风险和骨密度(BMD)有关,但结果仍存在争议。我们在此进行了一项荟萃分析,基于目前文献中可用的证据,更精确地评估这些关系。我们检索了 PubMed、Embase、Cochrane 图书馆、中国知网(CNKI)和万方数据库,以确定符合条件的研究。比值比(OR)、均数差(MD)和 95%置信区间(CI)用于评估这些关系的强度。我们的荟萃分析共纳入了 8 项研究,涉及 2632 名受试者。我们观察到 rs700518 的 AG 基因型与腰椎和股骨颈的 BMD 值较低显著相关(AG 与 GG:分别为 = .001 和.01)。然而,根据目前可用的数据,这种多态性对骨质疏松症的风险没有明显影响。总之,本荟萃分析表明,rs700518 多态性可能是骨质疏松症筛查、早期诊断和治疗的潜在候选生物标志物,有助于改善临床骨质疏松症患者的个体化治疗。